WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

KBC Group NV boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 53.8% during the 4th quarter, HoldingsChannel.com reports.The firm owned 2,151 shares of the company ...

Kymera Therapeutics (KYMR) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $9.62 million versus the consensus... Investing.com ...

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and ...

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), with a ...

WATERTOWN, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kymera Therapeutics, Inc. announced its participation in two upcoming investor events: the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare ...

Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases ...